1. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study 
Sune F Nielsen, PhD, Prof Børge G Nordestgaard, MD 
The Lancet Diabetes & Endocrinology 
Volume 2, Issue 11, Pages (November 2014)
DOI: /S (14)
Copyright © 2014 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Fibrates, bile acid sequestrants, nicotin acid and derivatives, and others (including ezetimibe). † Irregular use ascertained in the period before diabetes diagnosis; regular use defined as two prescriptions for statins, one obtained within 2 years before diabetes diagnosis and one within 6 months before diabetes diagnosis.
The Lancet Diabetes & Endocrinology 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

3. Figure 2
Cumulative incidence of microvascular diseases and gangrene according to statin use
Cumulative incidence among individuals with incident diabetes.
The Lancet Diabetes & Endocrinology 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions

4. Figure 3
Risk of microvascular diseases and gangrene, according to statin use
Risk in (A) the total population with diabetes, (B) after adjustment for the competing risk of death, and (C) after matching for propensity score.
The Lancet Diabetes & Endocrinology 2014 2, DOI: ( /S (14) )
Copyright © 2014 Elsevier Ltd Terms and Conditions